Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 3/20 | 0.41 |
| ▸ | XIAP | P98170 | 1/20 | 0.40 |
| ▸ | NPY1R | P25929 | 1/20 | 0.38 |
| ▸ | F7 | P08709 | 5/20 | 0.38 |
| ▸ | F3 | P13726 | 5/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26961959 | 1.00 | NPC1 (0.41) | NPC1SRCXIAPNPY1RF7 | |
| SCHEMBL26961889 | 0.93 | NPC1 (0.43) | NPC1SRCXIAPNPY1RF7 | |
| SCHEMBL29796781 | 0.93 | NPC1 (0.43) | NPC1SRCXIAPNPY1RF7 | |
| SCHEMBL26962156 | 0.92 | XIAP (0.44) | NPC1SRCXIAPNPY1RF7 | |
| SCHEMBL29796641 | 0.92 | XIAP (0.44) | NPC1SRCXIAPNPY1RF7 | |
| SCHEMBL29796999 | 0.92 | SRC (0.40) | NPC1SRCXIAPNPY1RF7 | |
| SCHEMBL26961709 | 0.91 | SRC (0.40) | NPC1SRCXIAPNPY1RF7 | |
| SCHEMBL29797006 | 0.91 | SRC (0.40) | NPC1SRCXIAPNPY1RF7 | |
| SCHEMBL26961716 | 0.88 | NPC1 (0.46) | NPC1SRCXIAPTP53SMN1; SMN2 | |
| SCHEMBL29796993 | 0.87 | NPC1 (0.43) | NPC1SRCXIAPNPY1RF7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4291558-A1 | BICYCLIC TETRAHYDROAZEPINE DERIVATIVES FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2023-12-20 | — | — | EP | disclosed |
| WO-2022171745-A1 | BICYCLIC TETRAHYDROAZEPINE DERIVATIVES FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2022-08-18 | — | — | WO | disclosed |